Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Depressive Disorder, Major | 188 | 2022 | 4735 | 15.380 |
Why?
|
Antidepressive Agents | 104 | 2024 | 2889 | 11.750 |
Why?
|
Ketamine | 15 | 2023 | 516 | 5.030 |
Why?
|
Fluoxetine | 35 | 2012 | 733 | 4.120 |
Why?
|
S-Adenosylmethionine | 15 | 2015 | 213 | 3.570 |
Why?
|
Citalopram | 14 | 2018 | 402 | 3.510 |
Why?
|
Antidepressive Agents, Second-Generation | 23 | 2016 | 489 | 3.350 |
Why?
|
Piperazines | 17 | 2020 | 2520 | 2.760 |
Why?
|
Double-Blind Method | 82 | 2022 | 12412 | 2.650 |
Why?
|
Thiazoles | 9 | 2018 | 1509 | 2.320 |
Why?
|
Bupropion | 11 | 2013 | 304 | 2.270 |
Why?
|
Antipsychotic Agents | 21 | 2020 | 3061 | 2.200 |
Why?
|
Drug Therapy, Combination | 51 | 2020 | 6499 | 2.080 |
Why?
|
Randomized Controlled Trials as Topic | 42 | 2022 | 10340 | 2.070 |
Why?
|
Placebo Effect | 9 | 2022 | 511 | 2.020 |
Why?
|
Psychiatric Status Rating Scales | 49 | 2024 | 6017 | 1.600 |
Why?
|
Tetrahydrofolates | 5 | 2016 | 58 | 1.600 |
Why?
|
Anxiety | 9 | 2020 | 4532 | 1.270 |
Why?
|
Drug Resistance | 25 | 2012 | 1617 | 1.230 |
Why?
|
Depressive Disorder | 18 | 2017 | 3728 | 1.150 |
Why?
|
Dysthymic Disorder | 3 | 2011 | 75 | 1.140 |
Why?
|
Treatment Outcome | 97 | 2024 | 64947 | 1.120 |
Why?
|
Urea | 5 | 2020 | 445 | 1.100 |
Why?
|
Anxiety Disorders | 10 | 2018 | 2711 | 1.060 |
Why?
|
Antidepressive Agents, Tricyclic | 9 | 2004 | 432 | 0.980 |
Why?
|
Homocysteine | 8 | 2012 | 640 | 0.980 |
Why?
|
Cognition Disorders | 7 | 2015 | 3976 | 0.950 |
Why?
|
Somatoform Disorders | 7 | 2008 | 423 | 0.920 |
Why?
|
Vitamin B 12 | 7 | 2012 | 522 | 0.870 |
Why?
|
Adrenergic Uptake Inhibitors | 4 | 2014 | 186 | 0.870 |
Why?
|
Panic Disorder | 6 | 2020 | 613 | 0.850 |
Why?
|
Fatigue | 6 | 2013 | 1544 | 0.830 |
Why?
|
Nortriptyline | 6 | 2003 | 79 | 0.810 |
Why?
|
Adult | 129 | 2024 | 219847 | 0.780 |
Why?
|
Humans | 226 | 2024 | 760261 | 0.760 |
Why?
|
Middle Aged | 114 | 2024 | 220175 | 0.710 |
Why?
|
Piperidines | 5 | 2020 | 1650 | 0.710 |
Why?
|
Placebos | 9 | 2012 | 1672 | 0.680 |
Why?
|
Nutrition Therapy | 1 | 2021 | 102 | 0.680 |
Why?
|
Cholinergic Agents | 2 | 2017 | 96 | 0.680 |
Why?
|
Folic Acid | 7 | 2012 | 1309 | 0.670 |
Why?
|
Sexual Dysfunction, Physiological | 5 | 2020 | 351 | 0.660 |
Why?
|
Trace Elements | 1 | 2021 | 196 | 0.660 |
Why?
|
Cyclohexanols | 4 | 2013 | 126 | 0.640 |
Why?
|
Mood Disorders | 3 | 2021 | 1123 | 0.640 |
Why?
|
Receptors, Opioid, kappa | 1 | 2020 | 138 | 0.630 |
Why?
|
Excitatory Amino Acid Antagonists | 2 | 2021 | 448 | 0.630 |
Why?
|
Male | 134 | 2024 | 359413 | 0.630 |
Why?
|
Aminopyridines | 2 | 2020 | 564 | 0.620 |
Why?
|
Serotonin Agents | 1 | 2018 | 29 | 0.610 |
Why?
|
Bipolar Disorder | 6 | 2022 | 5077 | 0.610 |
Why?
|
Pyrrolidines | 1 | 2020 | 338 | 0.600 |
Why?
|
Combined Modality Therapy | 9 | 2024 | 8551 | 0.590 |
Why?
|
Female | 135 | 2024 | 391011 | 0.590 |
Why?
|
Sulfides | 2 | 2015 | 171 | 0.590 |
Why?
|
Magnetic Field Therapy | 1 | 2017 | 27 | 0.590 |
Why?
|
Severity of Illness Index | 27 | 2020 | 15827 | 0.580 |
Why?
|
S-Adenosylhomocysteine | 2 | 2014 | 41 | 0.580 |
Why?
|
Personality Inventory | 12 | 2012 | 1018 | 0.570 |
Why?
|
Akathisia, Drug-Induced | 1 | 2017 | 67 | 0.570 |
Why?
|
Treatment Failure | 12 | 2020 | 2646 | 0.560 |
Why?
|
Prolactin | 4 | 2011 | 621 | 0.560 |
Why?
|
Serotonin 5-HT2 Receptor Antagonists | 3 | 2020 | 23 | 0.550 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2017 | 165 | 0.540 |
Why?
|
Acetamides | 1 | 2018 | 256 | 0.530 |
Why?
|
Disorders of Excessive Somnolence | 4 | 2008 | 277 | 0.520 |
Why?
|
Dietary Supplements | 3 | 2021 | 3389 | 0.520 |
Why?
|
Dopamine Uptake Inhibitors | 2 | 2008 | 297 | 0.520 |
Why?
|
Hypericum | 3 | 2014 | 58 | 0.510 |
Why?
|
Cholesterol | 5 | 2004 | 2925 | 0.490 |
Why?
|
Depression | 13 | 2022 | 8033 | 0.490 |
Why?
|
Narcotic Antagonists | 1 | 2020 | 582 | 0.490 |
Why?
|
Hydrocortisone | 6 | 2020 | 1798 | 0.490 |
Why?
|
Dose-Response Relationship, Drug | 20 | 2020 | 10829 | 0.480 |
Why?
|
Glutamates | 1 | 2015 | 391 | 0.470 |
Why?
|
Benzamides | 1 | 2020 | 1369 | 0.460 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2024 | 1469 | 0.460 |
Why?
|
Aldehydes | 1 | 2014 | 171 | 0.440 |
Why?
|
Pteroylpolyglutamic Acids | 1 | 2012 | 9 | 0.420 |
Why?
|
Dibenzothiazepines | 5 | 2014 | 102 | 0.420 |
Why?
|
Patient Dropouts | 3 | 2010 | 412 | 0.420 |
Why?
|
Vitamins | 1 | 2021 | 1635 | 0.410 |
Why?
|
Psychomotor Agitation | 1 | 2014 | 306 | 0.400 |
Why?
|
Infusions, Intravenous | 4 | 2022 | 2235 | 0.400 |
Why?
|
Hyperprolactinemia | 3 | 2010 | 123 | 0.390 |
Why?
|
Mianserin | 2 | 2008 | 50 | 0.380 |
Why?
|
Libido | 2 | 2011 | 119 | 0.380 |
Why?
|
Ambulatory Care | 13 | 2006 | 2783 | 0.370 |
Why?
|
Penile Erection | 1 | 2011 | 100 | 0.370 |
Why?
|
Sertraline | 3 | 2011 | 208 | 0.370 |
Why?
|
Drug Evaluation | 1 | 2012 | 642 | 0.360 |
Why?
|
Trazodone | 2 | 2008 | 68 | 0.360 |
Why?
|
Midazolam | 3 | 2022 | 267 | 0.360 |
Why?
|
Quinolones | 4 | 2012 | 377 | 0.350 |
Why?
|
Research Design | 8 | 2016 | 6181 | 0.350 |
Why?
|
Administration, Intranasal | 2 | 2023 | 471 | 0.350 |
Why?
|
Comorbidity | 18 | 2015 | 10552 | 0.340 |
Why?
|
Clonazepam | 1 | 2010 | 133 | 0.340 |
Why?
|
Adolescent | 42 | 2022 | 87747 | 0.340 |
Why?
|
Triiodothyronine | 2 | 2009 | 493 | 0.340 |
Why?
|
Buspirone | 1 | 2009 | 81 | 0.320 |
Why?
|
Phytotherapy | 2 | 2008 | 295 | 0.320 |
Why?
|
Serotonin | 3 | 2020 | 1041 | 0.320 |
Why?
|
Suicidal Ideation | 7 | 2021 | 1435 | 0.320 |
Why?
|
Serotonin Receptor Agonists | 1 | 2009 | 151 | 0.310 |
Why?
|
Psychometrics | 7 | 2020 | 3049 | 0.310 |
Why?
|
Drug Administration Schedule | 10 | 2010 | 4900 | 0.310 |
Why?
|
Weight Gain | 2 | 2017 | 2347 | 0.310 |
Why?
|
Young Adult | 25 | 2020 | 58673 | 0.310 |
Why?
|
Obesity | 6 | 2020 | 12915 | 0.300 |
Why?
|
Social Adjustment | 2 | 2015 | 632 | 0.300 |
Why?
|
Endocrine System Diseases | 1 | 2010 | 251 | 0.300 |
Why?
|
Regression Analysis | 8 | 2012 | 6361 | 0.300 |
Why?
|
Executive Function | 2 | 2016 | 1370 | 0.290 |
Why?
|
Plant Preparations | 1 | 2008 | 94 | 0.290 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 1799 | 0.290 |
Why?
|
Recurrence | 9 | 2019 | 8487 | 0.280 |
Why?
|
Moclobemide | 1 | 2006 | 4 | 0.280 |
Why?
|
C-Reactive Protein | 3 | 2019 | 3822 | 0.280 |
Why?
|
Mental Fatigue | 1 | 2006 | 22 | 0.280 |
Why?
|
Phobic Disorders | 1 | 2009 | 436 | 0.280 |
Why?
|
Imipramine | 1 | 2006 | 98 | 0.280 |
Why?
|
Psychotherapy | 5 | 2018 | 1640 | 0.270 |
Why?
|
Aged | 46 | 2020 | 168995 | 0.270 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 2006 | 155 | 0.270 |
Why?
|
Complementary Therapies | 1 | 2010 | 487 | 0.260 |
Why?
|
Personality Disorders | 4 | 2009 | 721 | 0.260 |
Why?
|
Norepinephrine | 3 | 2020 | 900 | 0.260 |
Why?
|
Remission Induction | 5 | 2016 | 2394 | 0.250 |
Why?
|
Thiophenes | 2 | 2009 | 587 | 0.250 |
Why?
|
Dopamine Agents | 1 | 2006 | 189 | 0.240 |
Why?
|
Triazoles | 2 | 2008 | 904 | 0.240 |
Why?
|
Desipramine | 5 | 2004 | 182 | 0.240 |
Why?
|
Saliva | 1 | 2009 | 816 | 0.240 |
Why?
|
Evidence-Based Medicine | 3 | 2012 | 3696 | 0.240 |
Why?
|
Cyclopropanes | 1 | 2006 | 431 | 0.240 |
Why?
|
Propylamines | 1 | 2005 | 161 | 0.240 |
Why?
|
Morpholines | 1 | 2007 | 583 | 0.230 |
Why?
|
Anger | 4 | 2010 | 401 | 0.230 |
Why?
|
Drug Synergism | 4 | 2017 | 1755 | 0.230 |
Why?
|
Panic | 2 | 2019 | 103 | 0.230 |
Why?
|
Analgesics, Opioid | 2 | 2017 | 3762 | 0.220 |
Why?
|
Electrocardiography | 1 | 2017 | 6413 | 0.220 |
Why?
|
Cognition | 4 | 2019 | 6948 | 0.210 |
Why?
|
Birds | 2 | 2001 | 168 | 0.210 |
Why?
|
Sample Size | 2 | 2020 | 840 | 0.210 |
Why?
|
Demography | 3 | 2016 | 1650 | 0.200 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2011 | 2197 | 0.200 |
Why?
|
Time Factors | 16 | 2019 | 40133 | 0.200 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 7 | 2010 | 1988 | 0.200 |
Why?
|
Dopamine | 2 | 2006 | 1583 | 0.200 |
Why?
|
Leptin | 3 | 2019 | 1590 | 0.190 |
Why?
|
Feathers | 1 | 2001 | 29 | 0.190 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2011 | 303 | 0.180 |
Why?
|
Lithium Carbonate | 4 | 2004 | 179 | 0.180 |
Why?
|
Suicide, Attempted | 2 | 2022 | 1387 | 0.180 |
Why?
|
Affective Symptoms | 1 | 2003 | 416 | 0.180 |
Why?
|
Nervous System Diseases | 1 | 2011 | 1647 | 0.180 |
Why?
|
Alcoholism | 1 | 2011 | 1961 | 0.180 |
Why?
|
MEDLINE | 2 | 2010 | 119 | 0.170 |
Why?
|
Nerve Net | 3 | 2017 | 2258 | 0.170 |
Why?
|
Obsessive-Compulsive Disorder | 1 | 2009 | 1488 | 0.170 |
Why?
|
Disabled Persons | 1 | 2009 | 1226 | 0.170 |
Why?
|
Happiness | 1 | 2020 | 170 | 0.160 |
Why?
|
Recovery of Function | 1 | 2009 | 2982 | 0.160 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39254 | 0.160 |
Why?
|
Drug Substitution | 2 | 2020 | 296 | 0.160 |
Why?
|
Tachyphylaxis | 1 | 2018 | 54 | 0.160 |
Why?
|
Brain-Derived Neurotrophic Factor | 2 | 2019 | 598 | 0.160 |
Why?
|
Comparative Effectiveness Research | 1 | 2024 | 718 | 0.160 |
Why?
|
Receptors, Melatonin | 1 | 2018 | 31 | 0.150 |
Why?
|
Electroconvulsive Therapy | 2 | 2022 | 502 | 0.150 |
Why?
|
Testosterone | 3 | 2020 | 2469 | 0.150 |
Why?
|
Mercury | 1 | 2001 | 290 | 0.150 |
Why?
|
Medication Therapy Management | 1 | 2019 | 132 | 0.150 |
Why?
|
Hostility | 2 | 2010 | 183 | 0.150 |
Why?
|
Globus Pallidus | 1 | 2019 | 249 | 0.150 |
Why?
|
Sex Characteristics | 3 | 2019 | 2627 | 0.150 |
Why?
|
Lithium | 4 | 2004 | 596 | 0.150 |
Why?
|
Serotonin Antagonists | 1 | 2018 | 144 | 0.140 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 629 | 0.140 |
Why?
|
Clinical Trials as Topic | 5 | 2015 | 8058 | 0.140 |
Why?
|
Motivation | 1 | 2007 | 1990 | 0.140 |
Why?
|
Probability | 3 | 2010 | 2476 | 0.140 |
Why?
|
Water Pollutants, Chemical | 1 | 2001 | 354 | 0.140 |
Why?
|
Environmental Monitoring | 2 | 2001 | 1441 | 0.140 |
Why?
|
Interpersonal Relations | 2 | 2004 | 1430 | 0.130 |
Why?
|
Single-Blind Method | 1 | 2020 | 1577 | 0.130 |
Why?
|
Inflammation | 1 | 2015 | 10757 | 0.130 |
Why?
|
Sleep Initiation and Maintenance Disorders | 3 | 2013 | 1076 | 0.130 |
Why?
|
Excitatory Amino Acid Agents | 1 | 2015 | 23 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 859 | 0.130 |
Why?
|
Thiazepines | 1 | 2015 | 30 | 0.130 |
Why?
|
Predictive Value of Tests | 5 | 2015 | 15273 | 0.120 |
Why?
|
Random Allocation | 1 | 2019 | 2394 | 0.120 |
Why?
|
Premenopause | 1 | 2019 | 1039 | 0.120 |
Why?
|
Circadian Rhythm | 2 | 2016 | 2567 | 0.120 |
Why?
|
History, 21st Century | 2 | 2019 | 1576 | 0.110 |
Why?
|
Long-Term Care | 2 | 2016 | 628 | 0.110 |
Why?
|
Brain | 7 | 2016 | 26912 | 0.110 |
Why?
|
Neurogenesis | 1 | 2020 | 855 | 0.110 |
Why?
|
Receptors, Serotonin | 1 | 2014 | 208 | 0.110 |
Why?
|
Adiponectin | 2 | 2019 | 1115 | 0.110 |
Why?
|
Mental Disorders | 3 | 2010 | 6797 | 0.110 |
Why?
|
Plant Extracts | 2 | 2014 | 495 | 0.110 |
Why?
|
Confidence Intervals | 2 | 2011 | 2932 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2019 | 966 | 0.110 |
Why?
|
European Union | 1 | 2013 | 157 | 0.110 |
Why?
|
Odds Ratio | 3 | 2011 | 9712 | 0.110 |
Why?
|
One-Carbon Group Transferases | 1 | 2012 | 6 | 0.110 |
Why?
|
Carnitine | 1 | 2014 | 251 | 0.100 |
Why?
|
Aging | 1 | 2011 | 8641 | 0.100 |
Why?
|
Reference Values | 3 | 2016 | 4920 | 0.100 |
Why?
|
Personality Assessment | 2 | 2005 | 650 | 0.100 |
Why?
|
Outpatients | 2 | 2019 | 1606 | 0.100 |
Why?
|
Histamine | 1 | 2014 | 499 | 0.100 |
Why?
|
Sleep Stages | 2 | 2006 | 685 | 0.100 |
Why?
|
Radioimmunoassay | 2 | 2009 | 866 | 0.100 |
Why?
|
Suicide | 1 | 2003 | 1599 | 0.100 |
Why?
|
Benzodiazepines | 3 | 2022 | 1132 | 0.100 |
Why?
|
Biological Availability | 1 | 2012 | 395 | 0.100 |
Why?
|
Research | 2 | 2018 | 1973 | 0.100 |
Why?
|
Prevalence | 6 | 2012 | 15687 | 0.090 |
Why?
|
Thalamus | 1 | 2017 | 1041 | 0.090 |
Why?
|
Resistin | 1 | 2011 | 172 | 0.090 |
Why?
|
History, 20th Century | 1 | 2019 | 2777 | 0.090 |
Why?
|
alpha 1-Antitrypsin | 1 | 2011 | 169 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2012 | 275 | 0.090 |
Why?
|
Light | 1 | 2016 | 1344 | 0.090 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2006 | 3695 | 0.090 |
Why?
|
Databases, Bibliographic | 1 | 2010 | 130 | 0.090 |
Why?
|
Apolipoprotein C-III | 1 | 2011 | 209 | 0.090 |
Why?
|
Neuropsychological Tests | 2 | 2015 | 7016 | 0.090 |
Why?
|
Antimanic Agents | 2 | 2004 | 520 | 0.090 |
Why?
|
Fluvoxamine | 1 | 2010 | 78 | 0.090 |
Why?
|
Addison Disease | 1 | 2010 | 48 | 0.090 |
Why?
|
Prospective Studies | 7 | 2018 | 54263 | 0.090 |
Why?
|
Hypnotics and Sedatives | 1 | 2018 | 1178 | 0.090 |
Why?
|
Methionine | 1 | 2012 | 569 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2011 | 346 | 0.080 |
Why?
|
Postmenopause | 1 | 2019 | 2503 | 0.080 |
Why?
|
Analysis of Variance | 4 | 2013 | 6242 | 0.080 |
Why?
|
Interleukin-6 | 2 | 2019 | 3207 | 0.080 |
Why?
|
Paroxetine | 1 | 2010 | 182 | 0.080 |
Why?
|
Child of Impaired Parents | 2 | 2003 | 459 | 0.080 |
Why?
|
Statistics as Topic | 2 | 2007 | 2363 | 0.080 |
Why?
|
Methadone | 1 | 2011 | 320 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2011 | 12281 | 0.080 |
Why?
|
Drug Discovery | 1 | 2017 | 1056 | 0.080 |
Why?
|
Epidermal Growth Factor | 1 | 2011 | 695 | 0.080 |
Why?
|
Peroxidase | 1 | 2011 | 604 | 0.080 |
Why?
|
Lepidium | 1 | 2008 | 8 | 0.080 |
Why?
|
Italy | 1 | 2010 | 840 | 0.080 |
Why?
|
Hyperthyroidism | 1 | 2010 | 291 | 0.080 |
Why?
|
Pharmacogenetics | 1 | 2012 | 680 | 0.080 |
Why?
|
Eicosapentaenoic Acid | 2 | 2009 | 613 | 0.080 |
Why?
|
Child Behavior Disorders | 2 | 2003 | 805 | 0.080 |
Why?
|
Secondary Prevention | 3 | 2010 | 1548 | 0.070 |
Why?
|
Pituitary ACTH Hypersecretion | 1 | 2010 | 178 | 0.070 |
Why?
|
Cardiovascular Diseases | 3 | 2011 | 15740 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2010 | 597 | 0.070 |
Why?
|
Quality of Life | 2 | 2013 | 13300 | 0.070 |
Why?
|
Terminology as Topic | 2 | 2006 | 1534 | 0.070 |
Why?
|
Opiate Substitution Treatment | 1 | 2011 | 435 | 0.070 |
Why?
|
Lithium Compounds | 1 | 2009 | 225 | 0.070 |
Why?
|
Anti-Anxiety Agents | 1 | 2010 | 397 | 0.070 |
Why?
|
Heart Rate | 1 | 2018 | 4169 | 0.070 |
Why?
|
Prefrontal Cortex | 1 | 2017 | 2212 | 0.070 |
Why?
|
PubMed | 1 | 2007 | 128 | 0.070 |
Why?
|
Body Mass Index | 2 | 2020 | 12901 | 0.070 |
Why?
|
Age Factors | 5 | 2011 | 18415 | 0.070 |
Why?
|
Risk Factors | 8 | 2010 | 74269 | 0.070 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2010 | 488 | 0.070 |
Why?
|
Aptitude | 1 | 2006 | 43 | 0.070 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2010 | 378 | 0.060 |
Why?
|
Logistic Models | 5 | 2009 | 13311 | 0.060 |
Why?
|
Case-Control Studies | 4 | 2019 | 22041 | 0.060 |
Why?
|
Juvenile Delinquency | 2 | 2003 | 116 | 0.060 |
Why?
|
Evoked Potentials | 1 | 2011 | 1031 | 0.060 |
Why?
|
Hypothyroidism | 1 | 2010 | 665 | 0.060 |
Why?
|
Dominance, Cerebral | 2 | 2016 | 622 | 0.060 |
Why?
|
Pilot Projects | 4 | 2011 | 8553 | 0.060 |
Why?
|
Impulsive Behavior | 2 | 2019 | 346 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2508 | 0.060 |
Why?
|
Mental Recall | 1 | 2011 | 1205 | 0.060 |
Why?
|
Patients | 1 | 2011 | 906 | 0.060 |
Why?
|
Nausea | 1 | 2008 | 677 | 0.060 |
Why?
|
Physician-Patient Relations | 2 | 2016 | 3242 | 0.060 |
Why?
|
Nervous System | 1 | 2008 | 543 | 0.060 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2016 | 2776 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2011 | 58947 | 0.060 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 1 | 2004 | 42 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2012 | 3531 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2015 | 4357 | 0.060 |
Why?
|
Retreatment | 1 | 2005 | 600 | 0.060 |
Why?
|
Sex Factors | 3 | 2007 | 10530 | 0.060 |
Why?
|
Fenfluramine | 1 | 2003 | 58 | 0.050 |
Why?
|
Problem Solving | 1 | 2006 | 440 | 0.050 |
Why?
|
Students | 1 | 2013 | 1722 | 0.050 |
Why?
|
Greece | 2 | 2001 | 336 | 0.050 |
Why?
|
Checklist | 1 | 2009 | 827 | 0.050 |
Why?
|
Androgens | 1 | 2009 | 1289 | 0.050 |
Why?
|
Medication Adherence | 2 | 2010 | 2163 | 0.050 |
Why?
|
Gastrointestinal Diseases | 1 | 2010 | 1189 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2012 | 4286 | 0.050 |
Why?
|
Genetic Markers | 1 | 2008 | 2608 | 0.050 |
Why?
|
Docosahexaenoic Acids | 1 | 2008 | 912 | 0.050 |
Why?
|
Drug Therapy | 1 | 2004 | 504 | 0.050 |
Why?
|
Nesting Behavior | 1 | 2001 | 17 | 0.050 |
Why?
|
Sleep | 1 | 2016 | 4746 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 3870 | 0.050 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2010 | 1387 | 0.050 |
Why?
|
Psychoses, Substance-Induced | 1 | 2021 | 99 | 0.040 |
Why?
|
Prognosis | 3 | 2008 | 29636 | 0.040 |
Why?
|
Electroencephalography | 2 | 2011 | 6182 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2003 | 988 | 0.040 |
Why?
|
Genotype | 1 | 2014 | 12959 | 0.040 |
Why?
|
Self Report | 1 | 2011 | 3707 | 0.040 |
Why?
|
Hypercholesterolemia | 2 | 2005 | 1155 | 0.040 |
Why?
|
Psychotropic Drugs | 1 | 2004 | 882 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2012 | 5507 | 0.040 |
Why?
|
Benzhydryl Compounds | 1 | 2006 | 942 | 0.040 |
Why?
|
Dissociative Disorders | 1 | 2021 | 233 | 0.040 |
Why?
|
Drug Prescriptions | 2 | 2006 | 1673 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2006 | 2434 | 0.040 |
Why?
|
Headache | 1 | 2006 | 1249 | 0.040 |
Why?
|
Risk Assessment | 2 | 2010 | 24086 | 0.040 |
Why?
|
Retrospective Studies | 6 | 2006 | 80301 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2696 | 0.040 |
Why?
|
Disability Evaluation | 1 | 2004 | 1826 | 0.040 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2021 | 498 | 0.040 |
Why?
|
Central Nervous System Stimulants | 1 | 2006 | 1169 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 5 | 2020 | 36247 | 0.030 |
Why?
|
Opioid-Related Disorders | 1 | 2011 | 2135 | 0.030 |
Why?
|
Physicians | 1 | 2014 | 4590 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14656 | 0.030 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2009 | 3201 | 0.030 |
Why?
|
Ranidae | 1 | 1996 | 32 | 0.030 |
Why?
|
Psychotic Disorders | 2 | 2009 | 3175 | 0.030 |
Why?
|
Population Surveillance | 1 | 2006 | 2609 | 0.030 |
Why?
|
Color | 1 | 2016 | 298 | 0.030 |
Why?
|
Child | 3 | 2022 | 79758 | 0.030 |
Why?
|
Pesticide Residues | 1 | 1996 | 95 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2004 | 2414 | 0.030 |
Why?
|
Hydrocarbons, Chlorinated | 1 | 1996 | 120 | 0.030 |
Why?
|
Magic | 1 | 1994 | 14 | 0.030 |
Why?
|
Osteoporosis | 1 | 2004 | 1600 | 0.030 |
Why?
|
Triglycerides | 1 | 2003 | 2476 | 0.030 |
Why?
|
Chronic Disease | 2 | 2007 | 9283 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2005 | 2753 | 0.030 |
Why?
|
Insecticides | 1 | 1996 | 191 | 0.030 |
Why?
|
Bone and Bones | 1 | 2004 | 2560 | 0.030 |
Why?
|
Diabetes Mellitus | 2 | 2010 | 5884 | 0.030 |
Why?
|
Gyrus Cinguli | 1 | 2020 | 1113 | 0.030 |
Why?
|
Body Weight | 1 | 2004 | 4613 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12968 | 0.030 |
Why?
|
Autonomic Nervous System | 1 | 2018 | 697 | 0.030 |
Why?
|
Body Temperature | 1 | 2016 | 777 | 0.030 |
Why?
|
Republic of Korea | 1 | 2015 | 567 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2021 | 1784 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14482 | 0.030 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 324 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2852 | 0.030 |
Why?
|
Age of Onset | 3 | 2005 | 3302 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2013 | 369 | 0.030 |
Why?
|
Schizophrenia | 2 | 2008 | 6915 | 0.030 |
Why?
|
Cytokines | 1 | 2007 | 7345 | 0.030 |
Why?
|
Science | 1 | 1994 | 240 | 0.020 |
Why?
|
Melatonin | 1 | 2016 | 668 | 0.020 |
Why?
|
Health Status | 1 | 2004 | 4081 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2006 | 3451 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2061 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5876 | 0.020 |
Why?
|
Animals | 5 | 2014 | 167940 | 0.020 |
Why?
|
Epilepsy | 2 | 1997 | 3267 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2014 | 961 | 0.020 |
Why?
|
Cost of Illness | 2 | 2013 | 1940 | 0.020 |
Why?
|
History, Ancient | 2 | 2003 | 211 | 0.020 |
Why?
|
Overweight | 1 | 2020 | 2421 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4276 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2001 | 3185 | 0.020 |
Why?
|
Hypertension | 3 | 2021 | 8595 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2006 | 25928 | 0.020 |
Why?
|
Universities | 1 | 2013 | 983 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2008 | 352 | 0.020 |
Why?
|
Plant Roots | 1 | 2008 | 117 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2009 | 711 | 0.020 |
Why?
|
Cross-Cultural Comparison | 1 | 2010 | 632 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2004 | 20048 | 0.020 |
Why?
|
Chi-Square Distribution | 2 | 2003 | 3466 | 0.020 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2008 | 189 | 0.020 |
Why?
|
Drug Combinations | 1 | 2012 | 2024 | 0.020 |
Why?
|
Consensus | 2 | 2006 | 3106 | 0.020 |
Why?
|
Primary Health Care | 2 | 2014 | 4649 | 0.020 |
Why?
|
Empirical Research | 1 | 2005 | 120 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2006 | 186 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 4370 | 0.010 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 934 | 0.010 |
Why?
|
Drug Costs | 1 | 2012 | 1184 | 0.010 |
Why?
|
History, Early Modern 1451-1600 | 1 | 2003 | 3 | 0.010 |
Why?
|
History, Modern 1601- | 1 | 2003 | 16 | 0.010 |
Why?
|
Self-Assessment | 1 | 2006 | 393 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 3335 | 0.010 |
Why?
|
Chemokines | 1 | 2007 | 962 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5324 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2010 | 1500 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2002 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2013 | 2218 | 0.010 |
Why?
|
Achievement | 1 | 2003 | 289 | 0.010 |
Why?
|
United States | 1 | 2009 | 72363 | 0.010 |
Why?
|
Brain Mapping | 1 | 2016 | 6562 | 0.010 |
Why?
|
Practice Guidelines as Topic | 2 | 2010 | 7468 | 0.010 |
Why?
|
Fatty Acids | 1 | 2008 | 1805 | 0.010 |
Why?
|
Creatinine | 1 | 2005 | 1906 | 0.010 |
Why?
|
Health Care Costs | 1 | 2012 | 3257 | 0.010 |
Why?
|
Smoking | 2 | 2005 | 9070 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2006 | 1266 | 0.010 |
Why?
|
Patient Care Team | 1 | 2010 | 2510 | 0.010 |
Why?
|
Hypogonadism | 1 | 2004 | 800 | 0.010 |
Why?
|
Lipids | 1 | 2009 | 3336 | 0.010 |
Why?
|
Acute Disease | 1 | 2007 | 7268 | 0.010 |
Why?
|
Greek World | 1 | 1994 | 6 | 0.010 |
Why?
|
Eggs | 1 | 1996 | 183 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2004 | 1881 | 0.010 |
Why?
|
Iraq | 1 | 1994 | 94 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2004 | 2080 | 0.010 |
Why?
|
Mass Screening | 1 | 2010 | 5422 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2006 | 3561 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2005 | 4012 | 0.010 |
Why?
|
Species Specificity | 1 | 1996 | 2413 | 0.010 |
Why?
|
Bone Density | 1 | 2004 | 3528 | 0.010 |
Why?
|
Data Collection | 1 | 2001 | 3317 | 0.010 |
Why?
|
Blood Glucose | 1 | 2006 | 6375 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2006 | 4440 | 0.010 |
Why?
|
Functional Laterality | 1 | 1997 | 2253 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 41317 | 0.010 |
Why?
|
Boston | 1 | 2003 | 9282 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13967 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 1997 | 5755 | 0.000 |
Why?
|
Hospitalization | 1 | 1997 | 10761 | 0.000 |
Why?
|